Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S. May 28, 2020. /George Frey/File Photo Acquire Licensing Rights
FRANKFURT, Oct 5 () - (This Oct. 5 factbox has been corrected to fix the entry on GLP-1 analogues to say the trial will likely be completed in mid-2023, not during the fourth quarter)
The following are facts about the new treatment options and what role they play in slowing the gradual progression of chronic kidney disease that can end in renal failure.
Lilly, Boehringer Say Jardiance Slows Kidney Disease Progression In Trial
Two classes of drugs, originally designed as diabetes treatments, have been found to have additional benefits to treat conditions that are major factors contributing to a deterioration of kidney function:
One new class of diabetes drugs known as SGLT2 inhibitors, including AstraZeneca’s (AZN.L) Farxiga as well as Boehringer Ingelheim and Eli Lilly’s (LLY.N) Jardiance, have been found to slow the decline of renal function and each is expected to reach annual sales of well over $3.5 billion over the next few years.
Farxiga won approval for the treatment of chronic kidney disease (CKD) last year. Jardiance is expected to gain access to the same market after a successful CKD trial in March.
New Treatment Options For Chronic Kidney Disease
Novo Nordisk’s (NOVOb.CO) Wegovy injection, a different repurposed diabetes drug with even higher sales potential, has been shown to help overweight people shed 35 pounds or more, reducing a major risk factor for kidney disease. Eli Lilly’s Mounjaro, a next-generation obesity drug candidate, has been billed as an even bigger blockbuster.
JP Morgan analysts have estimated annual peak sales of GLP-1 drugs at $34 billion in the obesity market with penetration expected to ramp from 1% in the United States now to 11% by 2031.
To overcome a view that body weight is primarily a lifestyle choice, Novo is running a trial that is expected to show the beneficial effect of GLP-1 on obese people's cardiovascular health. The company has said the trial will likely be completed in mid-2023.
Education Is Key To Engaging Patients With Kidney Disease
The initial weight loss from the drug is seen as a much-needed impetus that enables overweight patients to exercise more, starting a virtuous circle.
The two drug classes have the potential to tackle two of the most important risk factors contributing to kidney failure, or end-stage renal disease (ESRD), which requires life-saving dialysis to remove toxins and excess fluid from the blood.
Dialysis care costs U.S. Medicare more than $50 billion per year and the number of Americans on dialysis has been increasing at close to 2% per year.
None Oral Caspules Chronic Kidney Disease Herbal Medicine
Monthly U.S. spending per ESRD patient was over $14, 000, or 33 times more than on those without ESRD, according to University of Southern California research based on 2016 data.
Chronic kidney disease, which can lead to complete kidney failure over time, affects about 15% of U.S. adults or 37 million people, many of them not knowing they have it.[1/3]Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S. May 28, 2020. /George Frey/File Photo Acquire Licensing Rights
May 23 () - An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told , a move that could help identify patients eligible for new drugs that treat the disease earlier.
Reckeweg R64 Drops, Homeopathic Treatment Of Chronic Kidney Disease
The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults. That conclusion does not reflect the latest science and is now inactive, Dr. Carol Mangione, chair of the government-backed panel, said in an email.
A potential update is being driven in part by new drugs that can slow progression of a disease with no symptoms in its early stages but that can lead to kidney failure, which is fatal without dialysis filtering or a kidney transplant.
For a screening to help people live longer, healthier lives, clinicians must be able to treat the condition once it is found. The existence of effective treatments is one of many important factors that the Task Force considers, ” Mangione said.
Kidney Disease Linked To Acid Reflux Medication
Newer type 2 diabetes treatments known as SGLT2 inhibitors that work by prompting the kidneys to expel excess blood sugar through urine have been shown to have separate beneficial effects on the heart and kidneys.
AstraZeneca's (AZN.L) Farxiga won U.S. approval last year to slow progression of early-stage kidney disease. A large trial of Eli Lilly (LLY.N) and Boehringer Ingelheim's Jardiance was stopped in March after it became clear the drug was beneficial for kidney disease patients.
The National Kidney Foundation estimates that 37 million people in the United States have kidney disease, but around 90% do not know they have it. About 800, 000 are living with end-stage renal disease, requiring dialysis or a transplant to stay alive.
Popular Heartburn Drugs Linked To Gradual Yet 'silent' Kidney Damage
Most of kidney and cardiovascular disease is silent ... until something happens and then it is catastrophic, said Dr. Anjay Rastogi, director of the University of California Los Angeles kidney health program.
USPSTF recommendations often trigger insurance coverage for testing. Once the panel prioritizes an update of its screening recommendation, it would create a draft plan and post it for public comment. The full process could take as long as three years.
People with conditions such as hypertension and diabetes are at high risk of kidney disease, and several medical societies already recommend screening them for CKD. Diabetes is the leading cause of kidney failure, accounting for about 40% of new cases, the Kidney Foundation estimates.
Kidney Diseases: Symptoms, Causes, Treatment, Medicine, Prevention, Diagnosis
Because many cases go undetected, use of these older drugs is dismally low at around 25% to 40% of CKD patients, said Dr. Katherine Tuttle, a kidney disease expert at the University of Washington in Seattle.
Farxiga and Johnson & Johnson's (JNJ.N) Invokana were previously approved to treat type 2 diabetes patients with CKD. A recent study using March 2021 data from a large Boston health center found that just 6% of those patients had been prescribed an SGLT2 drug.
Updating the screening recommendations for CKD would be a step in the right direction toward combating this underdiagnosed disease, AstraZeneca said in an email.
Sriram Herbals Kidney Booster Medicine, Packaging Size: 120, Packaging Type: Bottle
Screening for kidney disease typically consists of a blood test for levels of a waste product called creatinine and a urine test for albumin, a type of protein.
The tests we're talking about, like a urine albumin test, are $10, said Tuttle, adding that it is not this testing that is breaking the healthcare budget.
Farxiga's U.S. list price is $533 for a 30-day supply, although AstraZeneca emphasizes patient assistance programs aimed at covering co-pays and the uninsured.
Medicines To Manage Kidney Disease
Many of these patients, if intervention is not made, they will end up on dialysis, said Sarah Walters, head of cardiovascular, renal and metabolism for AstraZeneca.The US Food and Drug Administration (FDA) has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are at the risk of progression with and without type-2 diabetes.
Farxiga can be used for lowering the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in CKD patients.
An oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor, Farxiga was granted priority review in the US for treating CKD patients in January this year.
Chronic Kidney Disease Drug Interactions
Data from this trial showed that Farxiga along with standard-of-care treatment provided a 39% reduction in the risk of worsening of renal function, ESKD onset, or risk of CV or renal death, the primary composite endpoint, versus placebo in stage 2-4 CKD patients with high urinary albumin excretion.
Furthermore, the absolute risk reduction (ARR) was 5.3% for a median time of 2.4 years while Farxiga also lowered the relative risk of death from any complication by 31% versus placebo.
AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “Today’s approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years.
Fda Accepts Application For Gsk's Chronic Kidney Disease Drug
“We’ve shown impressive efficacy for Farxiga in type-2 diabetes, heart failure with reduced ejection fraction and, most recently, chronic kidney disease and we are thrilled to be able to bring this medicine to millions of patients in the US.”
In another development, the US FDA has accepted the supplemental Biologics License Application of Bristol Myers Squibb for Opdivo (nivolumab) as adjuvant treatment for patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.
According to data from this trial, Opdivo showed a statistically significant and clinically meaningful increase in disease-free survival (DFS) compared to placebo irrespective of PD-L1 expression levels of the patient.
Kidney Failure Treatment
Sign up for our daily news round-up! Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights. close
0 comments:
Post a Comment